RLYB

Rallybio Corporation

A clinical-stage biotech focused on severe rare diseases, Rallybio is developing therapies like RLYB116, a once-weekly C5 inhibitor, and RLYB332, an antibody for iron-overload conditions. It was founded in 2018 by three former executives of Alexion Pharmaceuticals, who named the company for their mission to "rally" top scientists, partners, and resources from around the globe to pursue treatments other firms had passed over. In early 2026 it agreed to merge with the T-cell engager company Candid, with its legacy drug programs set to be sold off later through special Contingent Value Rights.